Bliss GVS Pharma Limited

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange about the resignation of a Director/KMP/SMP, but no further details are provided.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange regarding the cessation of Mr. Sachin Saboo as General Manager – Regulatory and Clinical, effective July 24, 2026, due to his resignation citing personal aspirations.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange about the publication of recommendations of the Committee of Independent Directors under Regulation 26(7) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended, regarding the open offer made by Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited to the public shareholders of Bliss GVS Pharma Limited for acquisition of up to 2,77,26,848 Equity Shares constituting 26.00% of the Expanded Voting Share Capital at a price of INR 299.00 per Offer Share.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange regarding the transfer of unclaimed Final Dividend 2018-2019 and its corresponding shares to the Investor Education and Protection Fund (IEPF) Authority, as per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange regarding the intimation of recommendations by the Committee of Independent Directors pursuant to Regulation 26(7) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 on Open Offer made by Anupam Rasayan India Limited together with Mates Visa Consultancy Private Limited to the Public Shareholders of Bliss GVS Pharma Limited.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange about a newspaper publication regarding the proposed transfer of unclaimed final dividend 2018-2019 and its corresponding shares to the Investor Education and Protection Fund (IEPF) Authority.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has received a Letter of Offer from SBI Capital Markets Limited for an open offer to acquire up to 2,77,26,848 equity shares, representing 26% of the expanded voting share capital, at ₹299.00 per share from public shareholders.

Bliss GVS Pharma Limited

SBI Capital Markets Ltd has submitted a letter of offer to the NSE regarding Bliss GVS Pharma Limited.

Bliss GVS Pharma Limited

SBI Capital Markets Limited has informed the Exchange about an addendum to the public announcement and detailed public statement for the open offer made by Anupam Rasayan Limited for the addition of PAC in Bliss GVS Pharma Limited.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange about an addendum to the public announcement and detailed public statement for the open offer made by Anupam Rasayan Limited, the acquirer for the addition of PAC.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 15, 2026, and informed the Exchange regarding voting results. The company has declared a 100% final dividend of ₹ 1.00 per equity share for the financial year ended March 31, 2026, and re-appointed Mr. Narsimha Shibroor Kamath as a Managing Director & CEO.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 15, 2026.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has updated the contact details of its Key Managerial Personnel (KMPs) responsible for reporting material events to stock exchanges.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has submitted a disclosure under SEBI Takeover Regulations, indicating a potential takeover or acquisition activity.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange regarding allotment of 187,750 securities pursuant to ESOP/ESPS at its meeting held on July 07, 2026, increasing the issued, subscribed & paid-up share capital of the Company.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange about the resignation of a Director/KMP/SMP.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has appointed Mr. Rahul Adakmol as Chief Executive Officer with effect from July 15, 2026, and Mr. Santosh Parab as an Additional Director in the capacity of Non-Executive Non-Independent Director with effect from July 03, 2026. Mr. Narsimha Shibroor Kamath has stepped aside from the position of Chief Executive Officer with effect from close of business hours on July 14, 2026.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange regarding Resignation of Mr Narsimha Shibroor Kamath as Chief Executive Officer of the company w.e.f. July 14, 2026. The Board of Directors has appointed Mr. Santosh Parab as an Additional Director and Mr. Rahul Adakmol as Chief Executive Officer.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has appointed Mr. Santosh Parab as a Non-Executive Director and Mr. Rahul Adakmol as the Chief Executive Officer, effective July 03, 2026 and July 15, 2026 respectively. Mr. Narsimha Shibroor Kamath has stepped aside as Chief Executive Officer and will continue as Managing Director.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on July 03, 2026. The Board of Directors has considered and approved the appointment of Mr. Santosh Parab as an Additional Director and Mr. Rahul Adakmol as Chief Executive Officer. Mr. Narsimha Shibroor Kamath has stepped aside from the position of Chief Executive Officer with effect from July 14, 2026.